Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction

Award Number: R44AG054386
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2016
PERIOD OF PERFORMANCE END DATE: 03/31/2020

Group Awards By:

View Award Description

Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction - The overall goal of this project is to develop a human protein that is an inhibitor of galectin-3, as a biologic to aid in the prevention and treatment of harmful remodeling after myocardial infarction (MI; heart attack) and, thereby, improve cardiac function and reduce mortality from subsequent heart failure. MI is the most common cause of cardiac morbidity and mortality in the Western world. The incidence in the United States is 610,000 new attacks and 325,000 recurrent attacks annually, approximately one every 34 seconds. Fibrosis is triggered by the physiological response to injury or infection and leads to the deposition of extracellular matrix and formation of new connective tissue. Excessive or dysregulated fibrosis from insults can dramatically reduce the functioning of the heart and other organs. In the heart, excessive interstitial fibrosis reduces contractility, elasticity, and distensibility, exacerbating processes that lead to heart failure. Although there are therapeutic agents currently used after MI that are efficacious, such as the mineralocorticoid receptor antagonists (MRAs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs), and that have shown anti-fibrotic effects in animal studies, the health burden from MI remains significant. Fibrosis is regulated by a number of inflammatory cytokines and growth factors, and galectin-3 has recently been implicated as a major and novel mediator of organ fibrosis. Increased serum levels of galectin-3 have been approved in the United States and the European Union as prognostic indicators of risk of death from progressive heart failure, supporting the hypothesis that galectin-3 is a target for drug development. Based on its mechanism of action and structure, the protein is a unique inhibitor of galectin-3 with properties that convey therapeutic advantage. Our preliminary studies in a rat ischemia reperfusion (I/R) injury model of MI showed very promising efficacy. The Specific Aims for this Fast Track Phase I/II project are the following: (Phase I) Aim 1 is to determine efficacy of Gal-3C therapy in animal models: Determine antifibrotic potential of Gal-3C in the context of greater injury caused by permanent ligation of the coronary artery, and evaluate efficacy of Gal-3C therapy relative to ARB and antifibrotic control drugs in a rat I/R MI model. (Phase II) Aim 2 is to better understand efficacy of Gal- 3C therapy in animal models: Determine efficacy and optimal dosage of Gal-3C in rat I/R MI; determine efficacy of Gal-3C in comparison to a MRA and in combination with an ARB in rat I/R MI model; and determine efficacy of Gal-3C in miniswine I/R model of MI. Aim 3 is to develop GLP/GMP production methods and a formulation for Gal-3C. Aim 4 is to perform pharmacokinetic studies and acute/subacute toxicology in rodents. Achievement of these aims is expected to position MandalMed to complete pre-clinical development in the near-term and to subsequently file an Investigational New Drug (IND) application.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2018	MANDALMED, INC.	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	3	11/8/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $1,193,236 )
2018	2018	MANDALMED INC	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	005	3	8/17/2018	SUPPLEMENT FOR EXPANSION	$131,530
2018	2018	MANDALMED INC	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	004	3	4/4/2018	NON-COMPETING CONTINUATION	$6,636
2018	2018	MANDALMED INC	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	002	3	3/6/2018	NON-COMPETING CONTINUATION	$1,054,447
2018	2017	MANDALMED INC	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	001	2	10/18/2017	EXTENSION WITH OR WITHOUT FUNDS	$20,718
2018	2017	MANDALMED INC	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	003	2	4/4/2018	EXTENSION WITH OR WITHOUT FUNDS	$623
2018	2016	MANDALMED INC	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	1	10/18/2017	NEW	-$20,718
														Subtotal = $1,193,236

Issue Date FY: 2017 ( Subtotal = $807,969 )
2017	2017	MANDALMED INC	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	001	2	4/10/2017	EXTENSION WITH OR WITHOUT FUNDS	$807,969
2017	2016	MANDALMED INC	665 3RD ST STE 250	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Aging Research	000	1	3/29/2017	NEW	$0
														Subtotal = $807,969

Issue Date FY: 2016 ( Subtotal = $224,734 )
2016	2016	MANDALMED, INC	665 3rd St Ste 250	San Francisco	CA	94107	SAN FRANCISCO	USA	Aging Research	000	1	8/15/2016	NEW	$224,734
														Subtotal = $224,734

Grand Total All Awards = $2,225,939

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction

Award Number: R44AG054386

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2016

PERIOD OF PERFORMANCE END DATE: 03/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer